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subgroup of patients (N473) eligible for evaluation under Method II was also eval-
uated under Method I, to assess differences in results compared with the overall
population. Method I yielded higher dose estimates when compared to Method II.
This was consistent for the total sample and subgroup. Ustekinumab cost per
injection in Method I was estimated up to 68.2% higher than in Method II. Variabil-
ity in cost estimates across doses was up to 18 times higher in Method I than
Method II. CONCLUSIONS: Conducting ustekinumab drug utilization assessments
with pharmacy claims requires a methodological adjustment to address multiple
doses dispensed on the same claim. Unadjusted assessment may yield artificially
high dose and cost estimates. Adjusted assessments offer a more realistic distri-
bution of dose and less variability in cost estimates. The ability to conduct adjusted
assessments requires the sample to have  2 ustekinumab prescriptions and suf-
ficient follow-up time.
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OBJECTIVES: The PROQOLID database was developed in mid-2001 to provide all
those involved in health care evaluation with a comprehensive and unique source
of information on Patient-Reported Outcomes (PRO) and Health-Related Quality of
Life (HRQL) measures available through the Internet. The objective of this study is
to review the evolution of content, structure, and functionality of the PROQOLID
database over this ten-year period (2002-2011). METHODS: The archives of PRO-
QOLIDwere searched to retrieve the database just before its launch and to compare
its content and structure as it is in December 2011. RESULTS: The September 2001
database (then known as QOLID) was retrieved. It included 313 instruments (32
generic and 281 disease- or condition-specific). Instruments specific to oncology
were themost frequent (54). The structurewas simplewith only three categories in
the membership level: contact, conditions of use, and a copy of the questionnaire.
By comparison, the December 2011 database includes 711 instruments (an increase
of 127%, with 99 generic and 612 disease- or condition-specific), with an increase of
almost 40 instruments each year (up by 398 in ten years). Instruments specific to
nervous system diseases are now the most frequent (139). The information dis-
played for each instrument has considerably been improved with the addition of
five categories in the membership level: translations available, descriptive infor-
mation, content validity documentation, measurement properties, references and
websites. A search engine has been added to enable advanced searches with the
following criteria: abbreviation, full name, author, dimension, disease, type of in-
strument, population, and languages. In January 2005 the database was renamed
PROQOLID to reflect the wider use of the term Patient-Reported Outcomes.
CONCLUSIONS: In a period of 10 years, the PROQOLID database has considerably
evolved in content, and structure, and offers a range of information and services
adapted to the evolution of the field.
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OBJECTIVES: Post-marketing surveillance for adverse effects has become an essen-
tial element of new drug andmedical devices development in the European Union
and the USA. The objective of this study is to present an overview of the content of
a database gathering the details of Regulatory Post-Marketing Studies (RPMS) re-
quested by the European Medicines Agency (EMA, EU), the Food and Drug Admin-
istration (FDA, USA) and the Haute Autorité de Santé (HAS, France).METHODS: All
drug approvals published by the EMA, the FDA and the HAS between January 1,
2005 and November 10, 2011 were reviewed to retrieve RPMS. The information was
categorized as follows: product description (brand name, INN, indication, etc.),
application details, RPMS details, and information source. RESULTS: For the FDA,
we reviewed 676 original approvals and 929 supplements and included, respec-
tively, 199 and 110 drugs approved with RPMS. For the EMA, we reviewed 333
marketing authorizations and included 33 files with RPMS. For the HAS, 3549 opin-
ions were published in this interval with only 174 opinions with RPMS. Many re-
quests of the HAS were long-term follow-up studies. About 43% of the RPMS re-
quested by the FDA were paediatric studies. Actually, the EMA also requires
paediatric studies but under a Paediatric Investigation Plan (PIP). Since 2005, 21 PIPs
have been requested. Whatever the agency, all kinds of indications are covered by
the RPMS, e.g., treatment of sepsis, asthma, malaria, depressive disorder, etc.
CONCLUSIONS: This project will be a unique source of centralized information
about RPMS requested in Europe and in the United States. It will be useful to
observe the current trends in studies requested, to anticipate the demands, and to
integrate the studies as early as possible in the product development process. The
database will be available online in an independent website, with access by sub-
scription.
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OBJECTIVES: Increasingly regulators and payers world-wide are seeking real world
data (RWD) to inform decisions on access to new medicines. While the ISPOR
International Digest of Databases is a valuable resource to facilitate the access of
health outcome researchers to RWD, a limitation is that it depends on database
providers to submit database information to ISPOR. In this researchwe aim to build
on this initiative by searching specifically in the therapeutic areas of oncology,
cardiology and endocrinology for databases that can assist researchers to identify
suitable databases in Europe and test whether they can answer relevant research
questions. METHODS: The search was limited to the United Kingdom, Germany,
France and the Netherlands using generalized research questions. Review of the
existing initiatives supplemented with interviews was conducted to set the final
framework of the research and refine the attributes relevant to the therapeutic
areas. Secondary research was conducted to identify real world databases not
captured previously. The database holders were contacted by phone and/or email
to obtain further information on the specifics of the databases. RESULTS: Five
previous initiatives including ISPOR were identified and reviewed. A total of 122
databases were identified and assessed. Of these, 86 databases (70%) were not
mentioned in any of the previous initiatives. Oncology databases formed the ma-
jority of the databases (57), followed by endocrinology (14) and cardiology (13with
the other 38 databases covered multiple therapeutic areas. Information was gath-
ered on general details, disease specific outcome measures, as well as technical
details. CONCLUSIONS: Our non-exhaustive research has shown that databases
with the potential to answer these hypothetical research questions do exist in all
countries. This research helps identify potential sources for RWD analysis, but in
practice a well-defined research question is needed to assess the true suitability of
the database.
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OBJECTIVES: It would be valuable for health care planning to project future popu-
lation co-morbidity conditions by studying the historical progression of patients
through the various possible health states, based on their initial health. This study
investigated a methodology of observing co-morbidity prevalence in the UK
population.METHODS: By using pre-collected data from The Health Improvement
Network (THIN) database of UK primary care records, the proportion of patients
who have one or more co-morbidities including hypertension, diabetes, heart dis-
ease, COPD and stroke can be observed for any given time period. A THIN data
extract was used to determine the transition rates between co-morbidity states, as
well as the mortality rates for each co-morbidity group. This was carried out by
‘measuring the central exposed to risk’, an actuarial analysis method, in each
group and using ‘forces of transition’ between the states. The number of doctor
visits which patients make per year, broken down by co-morbidity grouping, was
used as a potential proxy for historic demand for health services. RESULTS: Com-
bining data on the future population by age and sex, and the split between co-
morbidity groupings, we can estimate the total likely health service demand in the
future. CONCLUSIONS: This framework can be used to consider future scenarios,
seeking to address specific clinical issues or design policies that influence health
behaviour issues based on assumed changes in transition rates. For example, if
there were to be a one-year delay on the average age of diabetes onset, the impact
on the population’s health as well as the demand and cost of health provisions can
be estimated. Other examples of health scenarios that can bemodelled include the
effects of giving up smoking and reducing levels of obesity on co-morbidity and
thus the impact that lifestyle changes can have on future health service demand.
RESEARCH ON METHODS – Modeling Methods
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OBJECTIVES: Computer simulation studies of the emergency department (ED) of-
ten allow the patient to drive the process and do not consider indirect patient
related activities by the attending physician and resident (i.e. charting, teaching).
The objective of this study is to describe and evaluate an approach where physi-
cians are considered ‘pseudo-agents’ in a discrete event simulation (DES).
METHODS: Using data from an Ontario hospital, two ED DES models (traditional
versus pseudo-agent) were constructed and compared on key outputs including
time intervals and utilization rates. The traditional approachmodels the attending
physician and residents as human resources where their only function is to treat
patients. Additionally, residents are modeled similarly to the attending. The pseu-
do-agent approach allows for interaction between the attending physician and
residents, the use of different skill sets (attending treats more severe patients) and
decision-making hierarchy (physician prioritizes on treating a patient or teaching a
resident). These conceptswere implementedusing the simulation softwareARENA
13. RESULTS: Utilization of nursing staff and clerks remained similar. Physician
utilization rates increased by 50% in the pseudo-agent based model. There was no
change in the time from when the patient was placed in a room until the first
physician visit. Time until discharge or admission increased for patients with a
lower acuity in the pseudo-agent based model. As a result, time to room for these
patients also increased in addition to bed utilization. CONCLUSIONS: Computer
simulation models are more frequently being used to help inform hospital opera-
tional decision making. This example shows the importance of accurately model-
ing physician relationships and the rules in which they treat patients. Neglecting
these relationships could lead to inefficient resource allocation due to inaccurate
estimates of resource utilization and waiting times.
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